Work

Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs16-p6-11-09

Authors: AJ Brenner, G Falchook, M Patel, JR Infante, H-T Arkenau, EM Dean, E Borazanci, JS Lopez, K Moore, P Schmid, AE Frankel, S Jones, W McCulloch, G Kemble, K Grimmer, H Burris

Institutions: Institute of Cancer Research, Sarah Cannon Research Institute, The Christie NHS Foundation Trust, Tennessee Oncology, Barts Cancer Institute, University of Oklahoma Health Sciences Center, The University of Texas Southwestern Medical Center

Language: English

Topic: Cancer, Lipids, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2592933131

Cites:

Cited by: 19

Related to: 10